Literature DB >> 32738043

Personality Assessment Inventory Cognitive Bias Scale: Validation in a Military Sample.

Patrick Armistead-Jehle1, Paul B Ingram2, Nicole M Morris2.   

Abstract

OBJECTIVE: Recently, in a mixed neuropsychological outpatient sample, a measure of cognitive response bias has been developed for the Personality Assessment Inventory (PAI) called the Cognitive Bias Scale (CBS). This study sought to cross-validate this measure in a military sample.
METHOD: Retrospective review of 197 active duty soldiers referred to an Army outpatient clinic for neuropsychological evaluation. Groups were created based on the number of failed performance validity tests (0, 1, or 2-3 performance validity testing [PVT] failures).
RESULTS: The magnitude of effect for the 10-item CBS scale was medium-to-large when comparing those with one PVT failure to those with two to three (d = .98) and those with no failures (d = 1.21); however, effects between the 1 and 2-3 PVT failure groups were less pronounced. In 1 and 2-3 PVT failure groups, a score of $\ge$16 had high specificity (.92 and .95, respectively) and low to moderate sensitivity (.20 and .55, respectively).
CONCLUSIONS: In a military sample, the CBS demonstrated high specificity with relatively low sensitivity. The measure operated similarly to the original study and the current data supports the CBS to rule in, but not rule out, over-reported cognitive symptoms on the PAI.
© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  PAI CBS; military; symptom validity

Year:  2020        PMID: 32738043     DOI: 10.1093/arclin/acaa049

Source DB:  PubMed          Journal:  Arch Clin Neuropsychol        ISSN: 0887-6177            Impact factor:   2.813


  1 in total

1.  Validation of the Personality Assessment Inventory (PAI) scale of scales in a mixed clinical sample.

Authors:  Kaley Boress; Owen J Gaasedelen; Anna Croghan; Marcie King Johnson; Kristen Caraher; Michael R Basso; Douglas M Whiteside
Journal:  Clin Neuropsychol       Date:  2021-03-17       Impact factor: 4.373

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.